The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 867-872

  Kim, Soo A ^a   Kwon, Seong Min ^b   Yoon, Jung Hoon ^b   Ahn, Sang Gun ^b  

^a Dongguk University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Apoptosis; Heat shock factor 1; Oral cancer; Polo like kinase 1; siRNA

Indexed keywords

HEAT SHOCK TRANSCRIPTION FACTOR 1; POLO LIKE KINASE 1; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOMA CELL; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL DISRUPTION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN FADU; CONTROLLED STUDY; DRUG TARGETING; GENE SILENCING; HEP 2 CELL; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HEAT-SHOCK PROTEINS; HOT TEMPERATURE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 77749299415     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000564     Document Type: Article

References (31)

1. Donaldson MM, Tavares AA, Hagan IM, Nigg EA and Glover DM: The mitotic roles of Polo-like kinase. J Cell Sci 114: 2357-2358, 2001.
2. Nigg EA: Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 10: 776-783, 1998.
3. Mayor T, Meraldi P, Stierhof YD, Nigg EA and Fry AM: Protein kinases in control of the centrosome cycle. FEBS Lett 452: 92-95, 1999.
4. Noriyuki T, Ryoji H, Jun Y and Isao M: Polo-like kinases (Plks) and cancer. Oncogene 24: 287-291, 2005.
5. Knecht R, Elez R, Oechler M, Solbach C, VonIlberg C and Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794-2797, 1999.
6. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94: 148-152, 2003.
7. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A and Nishida E: Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410: 215-220, 2001.
8. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G and Marshall LA: The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 12: 405-411, 2000.
9. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M and Nakagawara A: Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549-25561, 2004.
10. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL and Luo Y: Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 64: 2698-2704, 2005.
11. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y and Maekawa T: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115: 978-985, 2005.
12. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M and Strebhardt K: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863-1877, 2002.
13. Liu X and Erikson RL: Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789-5794, 2003.
14. Sorger PK: Heat shock factor and the heat shock response. Cell 65: 363-366, 1991.
15. Morano KA and Thiele DJ: Heat shock factor function and regulation in response to cellular stress, growth and differentiation signals. Gene Exp 7: 271-282, 1999.
16. Morimoto RI, Jurivich DA, Kroeger PE, Mathur SK, Murphy SP, Nakai A, Sarge K, Abravaya K and Sistonen LT: Regulation of heat shock gene transcription by a family of heat shock factors. In: The Biology of Heat Shock Proteins and Molecular Chaperones. Morimoto RI, Tisieres A and Georgopoulos C (eds.) Cold Spring Harbor Press, New York, pp417-455, 1994.
17. Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell WC, Rabindran SK, Wu C and Roy-Burman P: A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 156: 857-864, 2000.
18. Cen H, Zheng S, Fang YM, Tang XP and Dong Q: Induction of HSF1 expression is associated with sporadic colorectal cancer. World J Gastroenterol 10: 3122-3126, 2004.
19. Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, Stevenson MA and Calderwood SK: Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 10: 46-58, 2005.
20. Ciocca DR and Vargas-Roig LM: Hsp27 as a prognostic and predictive factor in cancer. Prog Mol Subcell Biol 28: 205-218, 2002.
21. Ricaniadis N, Kataki A, Agnantis N, Androulakis G and Karakousis CP: Long-term prognostic significance of HSP-70, c-myc and HLS-DR expression in patients with malignant melanoma. Eur J Surg Oncol 27: 88-93, 2001.
22. Strik HM, Weller M, Frank B, Hermisson M, Deininger MH, Dichgans J and Meyermann R: Heat shock protein expression in human gliomas. Anticancer Res 20: 4457-4462, 2000.
23. Canto MT and Devesa SS: Oral cavity and pharynx cancer incidence rates in the United States 1975-1998. Oral Oncol 38: 610-617, 2002.
24. Mignogna MD, Fedele S and Russo LL: The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev 13: 139-142, 2004.
25. Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG and Yoon JH: Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res 13: 253-259, 2007.
26. Kim SA, Yoon JH, Lee SH and Ahn SG: Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress. J Biol Chem 280: 12653-12657, 2005.
27. Rossi A, Ciafre S, Balsamo M, Pierimarchi P and Santoro MG: Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res 66: 7678-7685, 2006.
28. Liu X and Erikson RL: Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 99: 8672-8676, 2002.
29. Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL and Schmidt M: Cell type-dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Mol Cancer Ther 6: 3189-3197, 2007.
30. De Carcer G, Do Carmo Avides M, Lallena MJ, Glover DM and Gonzalez C: Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. EMBO J 20: 2878-2884, 2001.
31. Simizu S and Osada H: Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2: 852-854, 2000.